@abc xyz No doubt - Alpex was a similar example for me; there were clear signs of growth visible before the listing - H1FY24 was more than FY23, 4x capacity addition in short term was disclosed in RHP & management walking the talk since then.
What is the equivalent for Winsol? 10% YoY growth? Order book worth 1 year sales? Neither are attractive. Management as
@MuStrFc says was not aggressive in his interviews. IPO price is cheap, but 250% GMP looking risky to enter - may work for a swing trade given hype.
Remember for Oriana also, the information kept on trickling in, with huge order wins throughout H2, and price kept ticking up, and H2 ended at 5x of H1 which was validation of amazing execution.